235 related articles for article (PubMed ID: 30301676)
1. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003.
Sasaki Y; Odan M; Yamamoto S; Kida S; Ueyama A; Shimizu M; Haruna T; Watanabe A; Okuno T
Bioorg Med Chem Lett; 2018 Dec; 28(22):3549-3553. PubMed ID: 30301676
[TBL] [Abstract][Full Text] [Related]
2. Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses.
Ecoeur F; Weiss J; Kaupmann K; Hintermann S; Orain D; Guntermann C
Front Immunol; 2019; 10():577. PubMed ID: 30972071
[TBL] [Abstract][Full Text] [Related]
3. Identification of Tetraazacyclic Compounds as Novel Potent Inhibitors Antagonizing RORγt Activity and Suppressing Th17 Cell Differentiation.
Ding Q; Zhao M; Yu B; Bai C; Huang Z
PLoS One; 2015; 10(9):e0137711. PubMed ID: 26368822
[TBL] [Abstract][Full Text] [Related]
4. Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
Gege C; Albers M; Kinzel O; Kleymann G; Schlüter T; Steeneck C; Hoffmann T; Xue X; Cummings MD; Spurlino J; Milligan C; Fourie AM; Edwards JP; Leonard K; Coe K; Scott B; Pippel D; Goldberg SD
Bioorg Med Chem Lett; 2020 Jun; 30(12):127205. PubMed ID: 32336498
[TBL] [Abstract][Full Text] [Related]
5. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.
Narjes F; Xue Y; von Berg S; Malmberg J; Llinas A; Olsson RI; Jirholt J; Grindebacke H; Leffler A; Hossain N; Lepistö M; Thunberg L; Leek H; Aagaard A; McPheat J; Hansson EL; Bäck E; Tångefjord S; Chen R; Xiong Y; Hongbin G; Hansson TG
J Med Chem; 2018 Sep; 61(17):7796-7813. PubMed ID: 30095900
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.
Guendisch U; Weiss J; Ecoeur F; Riker JC; Kaupmann K; Kallen J; Hintermann S; Orain D; Dawson J; Billich A; Guntermann C
PLoS One; 2017; 12(11):e0188391. PubMed ID: 29155882
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.
Fujita-Sato S; Ito S; Isobe T; Ohyama T; Wakabayashi K; Morishita K; Ando O; Isono F
J Biol Chem; 2011 Sep; 286(36):31409-17. PubMed ID: 21733845
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.
Wang Y; Cai W; Zhang G; Yang T; Liu Q; Cheng Y; Zhou L; Ma Y; Cheng Z; Lu S; Zhao YG; Zhang W; Xiang Z; Wang S; Yang L; Wu Q; Orband-Miller LA; Xu Y; Zhang J; Gao R; Huxdorf M; Xiang JN; Zhong Z; Elliott JD; Leung S; Lin X
Bioorg Med Chem; 2014 Jan; 22(2):692-702. PubMed ID: 24388993
[TBL] [Abstract][Full Text] [Related]
10. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations.
Imura C; Ueyama A; Sasaki Y; Shimizu M; Furue Y; Tai N; Tsujii K; Katayama K; Okuno T; Shichijo M; Yasui K; Yamamoto M
J Dermatol Sci; 2019 Mar; 93(3):176-185. PubMed ID: 30905492
[TBL] [Abstract][Full Text] [Related]
11. Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.
Olsson RI; Xue Y; von Berg S; Aagaard A; McPheat J; Hansson EL; Bernström J; Hansson P; Jirholt J; Grindebacke H; Leffler A; Chen R; Xiong Y; Ge H; Hansson TG; Narjes F
ChemMedChem; 2016 Jan; 11(2):207-16. PubMed ID: 26553345
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds.
Ding Q; Zhao M; Bai C; Yu B; Huang Z
BMC Immunol; 2015 May; 16():32. PubMed ID: 26021566
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting RORγt/Th17 axis for autoimmune disorders.
Isono F; Fujita-Sato S; Ito S
Drug Discov Today; 2014 Aug; 19(8):1205-11. PubMed ID: 24792721
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis.
Xue X; Soroosh P; De Leon-Tabaldo A; Luna-Roman R; Sablad M; Rozenkrants N; Yu J; Castro G; Banie H; Fung-Leung WP; Santamaria-Babi L; Schlueter T; Albers M; Leonard K; Budelsky AL; Fourie AM
Sci Rep; 2016 Dec; 6():37977. PubMed ID: 27905482
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
[TBL] [Abstract][Full Text] [Related]
17. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
[TBL] [Abstract][Full Text] [Related]
18. Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.
Kummer DA; Cummings MD; Abad M; Barbay J; Castro G; Wolin R; Kreutter KD; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Urbanski M; Venkatesan H; Wang A; Woods C; Xue X; Edwards JP; Fourie AM; Leonard K
Bioorg Med Chem Lett; 2017 May; 27(9):2047-2057. PubMed ID: 28318945
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present).
Sun N; Guo H; Wang Y
Expert Opin Ther Pat; 2019 Sep; 29(9):663-674. PubMed ID: 31403347
[No Abstract] [Full Text] [Related]
20. Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists.
Wang Y; Yang T; Liu Q; Ma Y; Yang L; Zhou L; Xiang Z; Cheng Z; Lu S; Orband-Miller LA; Zhang W; Wu Q; Zhang K; Li Y; Xiang JN; Elliott JD; Leung S; Ren F; Lin X
Bioorg Med Chem; 2015 Sep; 23(17):5293-302. PubMed ID: 26277758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
